AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04301999 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Photodynamic therapy
Description: The PDT optical fiber was inserted through the dilation catheterand advanced toward the bile duct stenosis point under visualradiography. The dilation catheter was then withdrawn to leavethe PDT optical fiber directly across the stricture. Photoactivation was performed at 640 nm using a diode laser at a light dose of 180 J/cm2at power density of300 mW/cm2 and irradiation time of 600 s.
Study NCT04301999 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: radiofrequency ablation
Description: an RFA electrode (Habib EndoHPB, EMcision, HitchinHerts, UK) was advanced along the guide wire into the bile duct and to the biliary stricture under X-ray fluoroscopic guidance. A 400 kHz RF generator (RITA 1500X, Angio Dynamics, USA) was connected for RFA at 7-10 W for 90 seconds.
Study NCT01883063 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Surgical Treatment
Description: Patients will be treated for distal radius fractures surgically with a WRx™ Intramedullary Nail
Study NCT01883063 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non surgical Treatment (Cast or splint)
Description: Patients will be treated for distal radius fractures non surgically with a cast or splint
Study NCT01884038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: treprostinil sodium
Description: A single dose strength of treprostinil sodium (1.0 mg/mL) and matching placebo will be provided in 20-mL multi-dose vials.~The study drug will be started after induction of anesthesia and increased incrementally to a target dose of 10 ng/kg/min during surgery and 48 hours post-operative
Study NCT01884038 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02771626 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: PD-1 inhibitor
Study NCT04658784 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 2-0 dioxanone, glycolide and trimethylene carbonate
Description: delayed absorbable, monofilament barbed suture
Study NCT04658784 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 2-0 polydioxanone
Description: delayed absorbable, monofilament non-barbed suture
Study NCT01423123 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 80 mg/m2 IV on days 1, 8, and 15 every 28 days until disease progression.
Study NCT01423123 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: trastuzumab
Description: 4 mg/kg IV loading dose, then 2 mg/kg IV weekly until disease progression.
Study NCT02378376 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Arabinoxylan oligosaccharides
Study NCT02378376 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary fiber enriched bran
Study NCT05521633 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin and Pioglitazone
Description: Every participant in Group-A took tablet metformin 500 mg daily and every participant in Group-B took tablet pioglitazone 30 mg daily.
Study NCT03014791 — intervention group
Intervention type: OTHER
Intervention: Brief lifestyle/medical history questionnaire
Description: Core Measurement
Study NCT03014791 — intervention group
Intervention type: OTHER
Intervention: Anthropometric measures
Description: Core Measurement
Study NCT03014791 — intervention group
Intervention type: OTHER
Intervention: Blood pressure and arterial stiffness
Description: Core Measurement
Study NCT03014791 — intervention group
Intervention type: OTHER
Intervention: Cardiac output and lung function
Description: Core Measurement
Study NCT02872090 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glycopyrronium
Description: inhalation
Study NCT02872090 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium
Description: inhalation
Study NCT01848470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CG400549 640mg
Description: multiple oral doses of 640 mg CG400549 (n=6) BID for 5 days (Days 1-5) and a final dose on Day 6 in the fed state
Study NCT01848470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CG400549 320 mg
Description: multiple oral doses of 320 mg CG400549 (n=6) QD for 5 days in the fed state
Study NCT01650038 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: treatment with faecal transplantation (donor faeces)
Description: faecal transplantation
Study NCT01650038 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: treatment with faecal transplantation (own faeces)
Description: faecal transplantation
Study NCT03014791 — intervention group
Intervention type: OTHER
Intervention: Heart rate variability
Description: Core Measurement
Study NCT03014791 — intervention group
Intervention type: OTHER
Intervention: Blood sample & spot urine sample
Description: Core Measurement
Study NCT01423123 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neratinib
Description: Dose level 1: 120 mg/day orally; Dose level 2: 160 mg/day orally; Dose level 3: 240 mg/day orally; Dose level 4: 200 mg/day orally.
Study NCT03014791 — intervention group
Intervention type: OTHER
Intervention: 24 hour ambulatory blood pressure monitor
Description: Detailed Measurement (Optional for participants).
Study NCT03014791 — intervention group
Intervention type: OTHER
Intervention: 24 hour urine collection
Description: Detailed Measurement (Optional for participants).
Study NCT03014791 — intervention group
Intervention type: OTHER
Intervention: Echocardiograph: Left ventricular mass
Description: Detailed Measurement (Optional for participants).
Study NCT03014791 — intervention group
Intervention type: OTHER
Intervention: Large artery structure: Carotid intima-media thickness
Description: Detailed Measurement (Optional for participants).
Study NCT03014791 — intervention group
Intervention type: OTHER
Intervention: Small artery structure: Minimum forearm vascular resistance
Description: Detailed Measurement (Optional for participants).
Study NCT03014791 — intervention group
Intervention type: OTHER
Intervention: Large artery endothelial function
Description: Flow- and salbutamol-mediated vasodilatation Detailed Measurement (Optional for participants).
Study NCT02618525 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Supraorbital pressure
Description: Supraorbital pressure is applied by applying pressure over the notch on the inner aspect of eyebrow.
Study NCT02618525 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jaw thrust maneuver
Description: Jaw thrust is performed by placing the index and middle fingers to physically pull the posterior aspects of the mandible upwards while their thumbs push down on the chin to open the mouth.
Study NCT02213653 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARM A : IV iron + epoietin zeta
Description: * Epoietin zeta at a dose of 450 IU / kg per week subcutaneously~* Carboxymaltose ferric (Ferinject ®) at week 1; Intravenous infusion not exceeding 1000 mg (administered once if weight> 50 kg, 500 mg twice otherwise, with an interval of one week between each administration).~  * Renewable with a minimum of 4 weeks depending on the iron status (if CST \<20% and absence of serum ferritin> 800) in the same manner as week 1.
Study NCT02213653 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARM B: IV iron + epoietin zeta sequence
Description: * Epoietin zeta at a dose of 450 IU / kg per week subcutaneously started in week 7~* carboxymaltose ferric (Ferinject ®) at week 1~  * Intravenous infusion not exceeding 1000 mg (administered once if weight> 50 kg, 500 mg twice otherwise, with an interval of one week between each administration).~ * Renewable with a minimum of 4 weeks depending on the iron status (if CST \<20% and absence of serum ferritin> 800) in the same manner as week 1.
Study NCT02213653 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ARM C : single epoietin zeta
Description: Epoietin zeta at a dose of 450 IU / kg per week subcutaneously begun in week 1
Study NCT04853095 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peritoneal fixation (PerFix)
Description: PerFix involves suturing the free end of the peritoneal flap left after RARP + ePLND to the pelvic wall near the symphysis of the pubic bones leaving two lateral openings for directing the lymphatic fluid out of the pelvis to the abdominal cavity.
Study NCT04853095 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: ePLND without peritoneal flap fixation
Study NCT04097873 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diaphragm ultrasonography reeducation plus inspiratory training
Description: Diaphragm biofeedback reeducation plus inspiratory training during 6 weeks
Study NCT04097873 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Isolated inspiratory training
Description: Isolated high-intensity inspiratory muscle training during 8 weeks
Study NCT03014791 — intervention group
Intervention type: OTHER
Intervention: Small artery endothelial function: Forearm blood flow
Description: Detailed Measurement (Optional for participants).
Study NCT01848470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CG400549 640 mg
Description: multiple oral doses of 640 mg CG400549 (n=6) QD for 5 days in the fed state
Study NCT03014791 — intervention group
Intervention type: OTHER
Intervention: Dundee step test
Description: Systolic blood pressure response to submaximal exercise Detailed Measurement (Optional for participants).
Study NCT02872090 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT01848470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CG400549 960 mg
Description: multiple oral doses of 960 mg CG400549 (n=6) QD for 5 days in the fed state
Study NCT01848470 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 640mg
Description: multiple oral doses of 640 mg placebo (n=2) BID for 5 days (Days 1-5) and a final dose on Day 6 in the fed state
Study NCT01848470 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 320mg
Description: multiple oral doses of 320 mg placebo (n=2) QD for 5 days in the fed state
Study NCT01848470 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo 960 mg
Description: multiple oral doses of 960 mg placebo (n=2) QD for 5 days in the fed state
Study NCT03014791 — intervention group
Intervention type: OTHER
Intervention: Detailed haemodynamic response to submaximal exercise
Description: Detailed Measurement (Optional for participants).
Study NCT01848470 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 640mg
Description: multiple oral doses of 640 mg placebo (n=2) QD for 5 days in the fed state
Study NCT02648217 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec/insulin aspart
Description: Injected subcutaneously (s.c., under the skin)twice daily. The pre-trial insulin will be discontinued.
Study NCT02648217 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: biphasic insulin aspart
Description: Injected subcutaneously (s.c., under the skin)twice daily. The pre-trial insulin will be discontinued.
Study NCT03759964 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferric carboxymaltose
Description: 1g of Ferric carboxymaltose diluted in 100 mL of IV isotonic serum saline at day 1 following surgery
Study NCT03759964 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 100 mL of IV isotonic serum saline at day 1 following surgery
Study NCT02872090 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: photoplethysmography
Description: inhalation
Study NCT03975907 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAR-BCMA T Cells
Description: The CAR-BCMA T cells (study drug) used in this study are chimeric antigen receptor specifically expressing T cells targeting BCMA.
Study NCT03133156 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: 10-Week Aerobic Exercise Training
Study NCT05132959 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: magnetic resonance imaging
Description: The MRI images of patients who had undergone to shoulder magnetic resonance imaging because of shoulder pain or another pathology were studied
Study NCT03479307 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bilastine Ophthalmic Solution 0.6%
Description: 1 drop in each eye at 2 separate times during an 8 day period.
Study NCT03479307 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketotifen Ophthalmic Solution 0.025% (Zaditen)
Description: 1 drop in each eye at 2 separate times during an 8 day period.
Study NCT03479307 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle of Bilastine Ophthalmic Solution
Description: 1 drop in each eye at 2 separate times during an 8 day period.
Study NCT02099097 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: web-based video game (Quit IT)
Study NCT02099097 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: In order to maximize survey the response rate, patients will be mailed a reminder letter approximately two weeks before the 1 month follow up surveys are due. If the survey is not returned, patients will be sent additional reminders on the survey due date as well as two weeks past the due date.
Study NCT02099097 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaires
Description: In order to maximize survey the response rate, patients will be mailed a reminder letter approximately two weeks before the 1 month follow up surveys are due. If the survey is not returned, patients will be sent additional reminders on the survey due date as well as two weeks past the due date.
Study NCT02099097 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Salvia sample
Description: The investigators will inform patients prior to obtaining their self-reports that a saliva test or expired CO sample for those using NRT or electronic cigarettes will be performed to examine recent tobacco exposure.
Study NCT02099097 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Salvia sample
Description: The investigators will inform patients prior to obtaining their self-reports that a saliva test or expired CO sample for those using NRT or electronic cigarettes will be performed to examine recent tobacco exposure.
Study NCT02447081 — intervention group
Intervention type: DEVICE
Intervention: Subjects implanted with Amulet Device
Description: Percutaneous Left Atrial Appendage occlusion with successful implant of occlusion device.
Study NCT02942446 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Investigative Headgear with CPAP mask
Description: Investigative Headgear with CPAP mask
Study NCT01631058 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: This is a 5-years prospective, randomized, exploratory, single-center, parallel group trial that includes renal transplanted elderly patients (≥ 60 years old) randomized between months 1 and 3 after transplantation to be maintained under MPS/TAC regimen or be switched to EVL/low-TAC.~Everolimus: initial dose of 1 mg BID. Doses will be adjusted in order to maintain Everolimus whole blood trough concentrations between 3-8 ng/ml.~Tacrolimus: initial dose of 0.1 mg/kg/day. Doses will be adjusted in order to maintain Tacrolimus whole blood trough concentrations between 2- 4 ng/ml thereafter.~Corticosteroids: as clinical practice.
Study NCT02867709 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ubrogepant
Description: Ubrogepant tablet(s) orally for the treatment of a qualifying migraine attack.
Study NCT02867709 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo-matching Ubrogepant
Description: Placebo-matching ubrogepant tablet(s) orally for the treatment of a qualifying migraine attack.
Study NCT02867709 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo-matching Ubrogepant
Description: Placebo-matching ubrogepant tablet(s) orally for the treatment of a qualifying migraine attack.
Study NCT03245008 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-5547
Description: Solution for injection in pre-filled syringe
Study NCT03245008 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-5547-matching placebo
Description: Solution for injection in pre-filled syringe
Study NCT03245008 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MT-5547-matching placebo
Description: Solution for injection in pre-filled syringe
Study NCT03079609 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: subinguinal microscopic varicocelectomy
Description: During the procedure approximately 1cm long fragment of varicose vein will be taken for further investigation.
Study NCT03079609 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: open hernia repair
Description: During the procedure approximately 1cm long fragment of spermatic cord vein will be taken for further investigation.
Study NCT01173718 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GORE® ACUSEAL Vascular Graft
Description: Surgical implantation of the GORE® ACUSEAL Vascular Graft for Hemodialysis per the Investigator's standard of practice.
Study NCT00939913 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: intravenous NAC
Description: intravenous regimen of NAC (1,200 mg bolus followed by 200 mg/hour for 24 hours)
Study NCT00939913 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Study participants will be randomized to receive an intravenous regimen of NAC (1,200 mg bolus followed by 200 mg/hour for 24 hours) or placebo.
Study NCT02406651 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Human Interleukin-22 IgG2-Fc (F-652)
Description: IV infusion of reconstitution lyophilized F-652.
Study NCT02406651 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Systemic Corticosteroids
Description: Prednisone (or equivalent) at the time of the onset of clinical symptoms consistent with GI and/or liver aGVHD, as per the standard of care. Prednisone (or equivalent) will be given at a dose of 2 mg/kg/day and tapered as needed.
Study NCT01454531 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVANZ Phleum pratense
Description: AVANZ Phleum pratense up-dosing phase (300, 600, 3000, 6000 and 15,000 SQ+) + one 15,000 SQ+ maintenance injection
Study NCT03531918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cladribine
Description: Given IV
Study NCT03531918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV
Study NCT03531918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemtuzumab Ozogamicin
Description: Given IV
Study NCT03531918 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Granulocyte Colony-Stimulating Factor
Description: Given SC
Study NCT03531918 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03531918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone Hydrochloride
Description: Given IV
Study NCT03647059 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: LSCM examination
Description: Cut a piece of donor liver and conduct the LSCM examination after staining fluorescein
Study NCT01022697 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Glucose drink
Description: 200 mL each 3 hours up to 8 cm of dilatation
Study NCT04495335 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: photobiomodulation
Description: Laser treatment will complete using Gallium-Aluminum-Arsenide (GaA1As) diode laser and application will complete by laser energy immediately and three times a week for just 15 days after surgery.
Study NCT04495335 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: photobiomodulation
Description: Laser treatment will complete using Gallium-Aluminum-Arsenide (GaA1As) diode laser and application will complete by laser energy immediately and three times a week for just 15 days after surgery.
Study NCT03014791 — intervention group
Intervention type: OTHER
Intervention: Cardiopulmonary fitness: Maximum oxygen consumption
Description: Detailed Measurement (Optional for participants).
Study NCT03014791 — intervention group
Intervention type: OTHER
Intervention: Haemodynamic response to mental stress
Description: Detailed Measurement (Optional for participants).
Study NCT03014791 — intervention group
Intervention type: OTHER
Intervention: Small artery dilatory function: Forearm blood flow
Description: Detailed Measurement (Optional for participants).
Study NCT01459952 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Rose hip Liquid
Description: Rose hip Liquid, 20 ml BID
Study NCT01459952 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Rose hip Liquid
Description: Rose hip Liquid, 20 ml BID
Study NCT03694899 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: phone contact
Description: patients will be called prior to their outpatient appointment
Study NCT03653884 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound monitoring
Description: Ultrasound monitoring is recommended during the third trimester in search of an increase in dilation and especially the appearance of a thrombus. A particular clinical form, related to abnormal umbilical vein involvement in the infra-hepatic portal system, must be individualized because of a high risk of thrombosis. It justifies the realization of an abdominal ultrasound in the first days of life. This is an aneurysm of the umbilical vein when the umbilical vein has a diameter greater than 9 mm, or a diameter of the subhepatic segment of the umbilical vein greater than 50% of the diameter of its intrahepatic segment.